Single‐cell RNA sequencing reveals microenvironmental infiltration in non‐small cell lung cancer with different responses to immunotherapy
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3736 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Xinnan Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Tumor Microenvironment, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project, Shanghai Nature Foundation Project.
Abstract (Originalsprache)
Background
Immunotherapy represents a groundbreaking and monumental achievement in the field of cancer therapy, marking a significant advancement in fighting against this devastating disease. Lung cancer has showed consistent clinical improvements in response to immunotherapy treatments, yet, it is undeniable that challenges such as limited response rates acquire resistance, and the unclear fundamental mechanisms were inevitable problems.
Methods
The cellular composition was defined and distinguished through single‐cell RNA sequencing (scRNA‐seq) analysis of MPR (major pathologic response) and NMPR (non‐major pathologic response) samples in GSE207422, including four primary MPR samples and eight primary NMPR samples.
Results
We found obvious difference in CD8+ T cell population between MPR and NMPR samples, with high expression of TYMS, RRM2, and BIRC5 in NPMR samples. Meanwhile, the proportion of macrophages and tumor epithelial cells infiltration increased in the NMPR samples. We discovered biomarkers (ACTN4, ATF3, BRD2, CDKN1A, and CHMP4B) in epithelial cells which were potentially represented worse outcomes.
Conclusions
By exploring the difference of tumor microenvironment (TME) in samples with different corresponding degrees of neoadjuvant immunotherapy, this research introduces a number of novel biomarkers for predicting the response of treatment and a theoretical basis for overcoming immunotherapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary, Hospital, School of Medicine, Tongji University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project
- Shanghai Nature Foundation Project
Zitieren
APA
Hu, X., Wu, Y., Wang, L., Yang, F., Ye, L., Chen, X., Song, X., & Wei, P. (2024). Single‐cell RNA sequencing reveals microenvironmental infiltration in non‐small cell lung cancer with different responses to immunotherapy. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3736
Vancouver
Hu X, Wu Y, Wang L, Yang F, Ye L, Chen X, et al. Single‐cell RNA sequencing reveals microenvironmental infiltration in non‐small cell lung cancer with different responses to immunotherapy. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3736
BibTeX
@article{Hu2024,
author = {Hu, Xinnan and Wu, Yonghui and Wang, Lixin and Yang, Fujun and Ye, Lingyun and Chen, Xiaoxia and Song, Xiao and Wei, Ping},
title = {Single‐cell RNA sequencing reveals microenvironmental infiltration in non‐small cell lung cancer with different responses to immunotherapy},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3736}
}
EUVIMED